Functional Analysis of Plasma Fibronectin with Special Consideration of Binding Interferences by Köttgen, E. et al.
Kotigen et al.: Functional analysis of plasma fibronectin 541
J. Clin. Chem. Clin. Biochem.
Vol. 24, 1986, pp. 541-549
© 1986 Walter de Gruyter & Co.
Berlin · New York
Functional Analysis of Plasma Fibronectin
with Special Consideration of Binding Interferences
By E. Kotigen, S. Hoeft, Ch. Müller and B. Hell
Institut für Klinische Chemie und Biochemie, Klinikum Charlottenburg, Freie Universität Berlin, Berlin, FRG
(Received January 17/March 24, 1986)
Dedicated to Prof. Dr. W. Gerok on the occasion ofhis 60th birthday
Summary: So far, soluble fibronectin has been quantitated mostly by immunological techniques. In this
investigation we show that an immunological assay provides reliable results only with intact fibronectin.
Fibronectin fragments resulting from proteolysis give rise to falsely raised values. We present four functional
tests based on the sandwich (ELISA) technique on microtitre plates. These quantify fibronectin on the basis
of its binding capacity to collagen, heparin/fibrin and carboxy-group-modified IgG with high sensitivity,
specificity and precision. Analysis of the bioactivity spectrum of intact fibronectin is not disturbed by
fibronectin fragments. Furthermore we demonstrate interferences, in particular between heparin and collagen
in their mutual binding to fibronectin. This provides new indications of a "substrate activation" of fibronectin.
Funktionsorientierte Quantifizierung von Fibronectin unter besonderer Berücksichtigung von Bindungsinterferen-
zen
Zusammenfassung: Die Quantifizierung von löslichem Fibronectin im Plasma erfolgt bisher weitgehend über
rein immunologische Verfahren. In der vorliegenden Untersuchung wird gezeigt, daß diese immunologische
Konzentrationsbestimmung nur bei intaktem Fibronectin korrekte Ergebnisse ergibt. Proteolytische Fibronec-
tin-Fragmente liefern falsch erhöhte Werte. Als Alternative zur immunologischen Konzentrationsbestimmung
werden vier Fibronectin-Funktionsteste nach der Sandwich-(ELISA-) Technik auf Mikrotiterplatten vorge-
stellt, die die Bindungskapazität von Fibronectin gegenüber Kollagen, Heparin, Fibrin und Carboxygruppen-
modifiziertem IgG mit hoher Nachweisempfindlichkeit, Spezifität und Präzision quantifizieren. Die Analyse
des Fibronectin^Bindungsspektrums wird nicht durch Fibronectin-Fragmente gestört. Zwischen immunologi-
scher und biologischer Reaktivität bestehen daher nur bei intakter Proteinstruktur Beziehungen. Weiterhin
werden Interfereiizen insbesondere zwischen der Heparin- und der Kollagen-Bindung demonstriert, die erneut
Hinweise auf eine „Substrat-Aktivierung" von Fibronectin geben.
Introduction fibronectin (MT = ca. 440000) is a dimer with two
Fibronectin is the term used today for a high molecu- polypeptide chains connected via two disulphide
lar weight glycoprotein, which has previoüsly been bridges. Additional intrachain S-S bridges contribute
known under various names. The protein is of great to the formation of a typical tertiary structure charac-
interest for biochemical studies in cell biology and terized by four globular domains with protease-sensi-
medicine (l, 2, 3). The molecule is synthesized by tive connecting units. The glycosylation and phos-
various types of cells and is localized on the cell phorylation of the protein can show maturation- and
surface äs a fibrillar polymer. The soluble plasma organ-specific variations (3, 5, 6).
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The domains mentioned above can be isolated by
limited proteolysis (7, 8). The domains are charac-
terized by their differing capacity for binding primar-
ily either collagen, glycosaminoglycans (especially
heparin) and fibrin, with additional affinities to com-
plement factor Clq, actin, DNA and gangliosides.
The C-terminal domain additionally binds proteins
with modified carboxyl groups such äs IgG (9,10).
Due to these multiple ligand properties, fibronectin
is involved in many biological functions, such äs cell
adhesion, chemotaxis, immunomodulation, bacterial
tissue tropism, wound repair and in blood coagula-
tion (2). Fibronectin is gaining additional medical
significance, since appreciable alterations of the
plasma fibronectin concentrations can be observed in
the plasma of patients with inflammatory diseases äs
well äs in shock patients (11, 12, 13).
In addition, the differentiation of a 'malignant' from
a 'benign' ascites is possible by determining the fi-
bronectin concentration in ascites (14). However, the
majority of these results is based exclusively on immu-
nological quantification of fibronectin in which al-
tered functionality of the various domains is not
reflected. Furthermore, these investigations do not
take into consideration the extent to which function-
reduced proteolytic fibronectin fragments may influ-
ence the quantitation of intact fibronectin. Enhanced
proteolytic activity can be found for example in ma-
lignant ascites, äs well äs in the plasma of patients
with acute pancreatitis or disseminated intravascular
coagulation with fibrinolytic states.
In the results presented, we describe a test battery
based on an ELISA-equivalent test procedure en-
abling quantification of four domain-specific
functions of fibronectin. Furthermore, we present
comparative investigations on functional interference
with the fibronectin binding capacity.
Materials and Methods
Rabbit anti-human fibronectin and rabbit anti-human-fibro-
nectin-peroxidase conjugate were obtained from Dakopatts
(Copenhagen, Denmark), thermolysin from Boehringer
(Mannheim, FRG), thrombin from Behringwerke (Marburg,
FRG), bovine serum albumin and 3,3', 5,5'-tetramethylbenzi-
dine (rom Miles Lab. (Munich, FRG), and hydroxyapatite
(DNA grade) from Bio Rad (Munich, FRG). -Aminocaproic
acid, heparin-agarose, peroxidase, heparin-sodium salt, gelatine
(calf skin), fibrinogen (bovine), glycine ethyl ester, Tween 20 and
3-amino-9-ethylcarbazole were obtained from Sigma (Munich,
FRG), gelatine-sepharose from Pharmacia (Uppsala, Sweden),
nitrocellulose membranes (0.45 pore size) from Biotec
Fischer (Reiskirchen, FRG). Ali other reagents were purchased
äs analytical grade from E. Merck (Darmstadt, FRG).
For the ELISA technique, imrnuno-microtitre plates from
NUNC (Wiesbaden, FRG) and Titertek-Multiscan (Flow
Labs.) were used. For the polyacrylamide gel electrophoresis,
the flat bed gel electrophoresis from Pharmacia, and for the
Western blot the Biotec Fischer (FRG) facility was applied.
Buffers
(i) Phosphate buffer: 57,9 mmol/1 Na2HPO4, 8.8 mmol/1
KH2P04, pH 7.6;
(ii) Phosphate buffer, containing bovine serum albumin and
EDTA: phosphate buffer (i) 4- 5 mmol/1 EDTA + 5 g/l bovine
serum albumin;
(iü) Phosphate buffer, containing Tween: phosphate buffer (i)
+ 0.5 g/l Tween 20;
(i v) blotting transfer buffer: 12.5 mmol/1 Tris, 96 mmol/1 glycine,
0.1 g/l SDS, 200 g/l methanol, pH 8.3;
(v) blocking buffer (Western blot): 10.0 mmol/1 Tris, 150 mmol/1
NaCl. 5 g/l bovine serum albumin, 0.5 g/I Tween 20, pH 7.4.
Fibronectin Isolation
Fibronectin was prepurified from citrate-plasma by afrraity
chromatography on gelatine-sepharose in buffer (i) with 10
mmol/1 -aminocaproic acid, 5.0 mmol/1 EDTA fpliowed by a
specific elution with 50 mmol/1 Tris, 4 mol/1 urea, pH 7.6.
The fibronectin was additionally purified on heparin-sepharose
(washing buffer: 10 mmol/1 Tris* pH 7.6; elution: 10 mmol/1
Tris, 0.5 mol/1 NaCl, pH 7.6) (15). In the SDS-pplyacrylamide
gel electrophoresis, the typical double bands are found exclu-
sively at MT = 220000. The protein determination is carried
out according to Lowry or by phptometric measurement at 280
nm (fibronectin [10 g/l] A2eo <1 cin> = 12.8) (16). After addition
of NaN3 (0.1 g/l) the purified protein can be stored at 4 °C for
at least eight weeks.
Fibronectin proteolysis
Thermolysin and fibronectin l : 200 (weight ratip) were
bated for different times (see results) at 20 °C in 60 mmol/1
Tris, 3.0 mmol/1 CaCl2, pH 7.6 (7). The proteolysis is terminated
by addition of 0.2 mol/1 EDTA (final concentration in the test
mixture 10 mmol/1 EDTA).
Polyacrylamide gel electrophoresis
The SDS-polyacrylamide gel electrophoresis was carried out
under reducing conditions in the buffer System according to
Läemmli (20) with a 3.5% stacking gel, a linear gradient-gel
(5—12%) and a Separation distance of 13 ein. The proteins
were fixed and stained in a solution containing acetic acid (70
g/l) - methanol (l + 2 by vol.) and Coomassie blue (1.0 g/l).
Western blot
Proteins were transferred from the polyacrylamide gel electro-
phoretically at 100 volts for one hour onto nitrocellulose sheets
according to Towbin (19). After blocking the free binding sites
on the nitrocellulose membrane for 16h (blocking buffer see
above), the membrane was incubated for l h with shaking in
a l : 1000 dilution (by vol.) of perojcjdase-labeled antibody in
buffer (ii). After washing three times in buffer (iii), the menv
brane was stained with aminoethylcarbazole.
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Hydroxyapati te chromatography
Fibronectin was equilibrated in washing buffer (2 mmol/1 so-
dium phosphate buffer, l mmol/1 EDTA, pH 6.8) and 100 mg
protein was applied to the column (l .5 χ 25 cm). The specific
elution was carried out in a linear gradient up to 200 mmol/1
sodium phosphate (18).
Enzyme-linked-immuno-sorbent-assays (ELISA)
The assays were performed in accordance with the "sandwich
technique" with biological ligands fixed to polystyrene. For
detection of bound fibronectin, peroxidase-conjugated anti-
fibronectin was used. Tetramethylbenzidine (80 mg/I dissolved
in 160 mmol/1 acetate/citrate buffer, 1.3 mmol/1 H2O2, pH
6.0) served s Substrate. The product formation at 25 °C was
quantified after 20 min at 620 nm. AU washing proccdures were
identical in the subsequent tests.
Antibody assay
Pipette 100 μΐ antibody solution (rabbit anti-human fibronectin,
diluted l : 2000 with phosphate buffer (i)) into the wells and
incubate for 16 h at 4 °C for adsoφtion. Wash the plates three
times with buffer (iii), then add a sample of 150 μΐ (diluted in
buffer (ii)). For plasma, dilution to 1:10000 is necessary.
Incubate the test mixture for 2.5 h at 25 °C and wash three
times with buffer (iii). Add 125 μΐ peroxidase labeled antibody
(l : 1000 diluted in buffer (ii)), incubate for one hour at 25 °C
and wash again three times with buffer (iii). Add 125 μΐ Sub-
strate solution and measure the product formation s described
above.
Heparin assay
Transfer 100 μΐ of heparin solution (100 U/l = 0.6 g/l in
phosphate buffer (i)) into the wells s described above. Add
120 μΐ sample material (dilution in buffer (ii); for plasma
samples l: 1000). Further procedure s above.
Fibrin assay
Bovine fibrin is used s ligand. For this purpose, the microtitre
plate is coated with fibrinogen, which is subsequently degraded
to fibrin by thrombin. Since the fibrinogen preparation is
contaminated with fibronectin, and hence cross-reacts with
the antibody used, fibrinogen must be purified by affinity
chromatography on gelatine-sepharose (see above).
Place 100 ul purified fibrinogen solution (0.1 g/l in phosphate
buffer (i)) into the wells and incubate over 3 h at 25 °C in a
moist chamber. After triple washing add 125 ul thrombin solu-
tion (0.4 U/ml in phosphate buffer (i)) and incubate the plates
for 16 h at 4 °C. After finishing the washing Steps s described
above, add 120 μΐ diluted sample (in phosphate buffer (ii)); for
plasma samples dilute l: 100 and proceed s described.
Carboxyl group-modified IgG assay
Human immunpglobulin IgG is modified at the carboxyl-
groups (IgGmo<|) by coupling glycine ethyl ester to the protein
in the presence of carbodiimide (9, 17). Add 100 μι of the
modified IgG (10 mg/1 in phosphate buffer (i)) s ligand to the
solid phase. After washing, pipette 120 μΐ diluted sample
(plasma l : 1000) into the wells and incubate for 90 min, In
this test, add 2.5% (by vol.) rabbit serum to the enzyme-labeled
antibody in order to ayoid the nonspecific binding of the
antibody to the modified IgG. The further quantification of
binding is carried out s described.
Gelatine assay
Cover the microtitre plates with 100 μΐ gelatine solution (2.5 g/l
in phosphate buffer (i)). The further procedure is s described in
the antibody assay. Plasma samples are diluted l : 10000.
For the analysis of plasma, EDTA-plasma with addilion of
l TlU/ml (trypsin inhibiting unit) aprotinin (Trasylol®) is gen-
erally used. For the comparative immunoturbidimetric fi-
bronectin quantification, the 'Fibronectin' test kit from
Boehringer (Mannheim, FRG) is used.
Results
As a basis for the following function-specified binding
assays, we determined fibronectin in the ELISA test
on microtitre plates (antibody assay). We used both
purified fibronectin s well s plasma samples. With
both materials, the fibronectin concentration can be
quantified over a concentration r nge of l μg/l to 32
μg/l. This means a detection limit of 0.16 ng fibronec-
tin. The typical shape of the Standard curve is shown
in figure 1. In this s well s the other Systems,
the absorbance of the lowest detectable fibronectin
concentration is defined s the threefold Standard
deviation of the blank value.
Since the immunological reactivity of fibronectin can-
not provide reliable information on alterations of
defined fibronectin functions, we developed different
ELISA-equivalent procedures, each one quantifying
a specific fibronectin binding property. In all assays
the microtitre plates were first coated with the specific
ligand, then incubated with the fibronectin-contain-
ing sample. The ligand-bound fibronectin was quanti-
fied by a peroxidase-labeled anti-fibronectin anti-
body. After lyophilisation, all ligand-coated carriers
can be stored at 4 °C for at least eight weeks.
The collagen-binding capacity of fibronectin was
tested in the gelatine assay. Figure l shows the typical
calibration curve. The measuring r nge extends from
1.6 μg/l—50 μ%/1. This corresponds to a detection
limit of 0.2 ng fibronectin per well.
The fibronectin-heparin affinity was quantified via
an appropriate test System. The measuring r nge here
was 200 μg/l —125 mg/1 (detection limit 24 ng fi-
bronectin).
We found the fibrin binding assay to have the lowest
sensitivity (3 mg/1—200 mg/1; detection limit 0.36 μg
fibronectin).
Since fibronectin possesses an additional binding site
for carboxyl group-modified proteins in its C-ter-
minal domain, we developed an assay for these li-
gands. As can be seen from figure l, we found that
this assay gave the widest measuring r nge (25
μ^ —1.6 mg/1) and a good limit of detection (3.0 ng
fibronectin).
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Measurement ranges for concentration and binding affmity analysis of fibronectin.
The various ELISA test procedures detect the concentration (antibody assay) or binding affmities (gelatine assay, carboxyl
group-modified IgG binding assay, heparin assay, fibrin assay) in different measurement ranges. Purified fibronectin
served äs sample material in each case. Each measurement value corresponds to the mean value of triple determination.
Corresponding analysis of plasma can be carried out by means of the available reference curves.
In table l, the results on within-run and between-run
imprecision are summarized for all tests mentioned.
We obtained identical results when using both puri-
fied fibronectin or plasma. To plot reference Standard
curves and to check the accuracy, we used commercial
fibronectin Standards (Boehringer Mannheim) äs well
äs fibronectin we had purified ourselves. The quanti-
tative protein assay of the purified fibronectin corre-
sponded exactly with the fibronectin concentration
determined immunologically with the commercial fi-
bronectin Standard! Recovery trials with purified fi-
bronectin and commercial fibronectin Standards
showed a mean deviation of the target value of 3%.
For optimization of the technique, we examined, for
all test Systems, the influence of ionic strength and
pH on the binding of fibronectin bound to the solid
Tab. 1. Within-run and between-run imprecision of the fi-
bronectin assays. The studies were performed with one
lot of ligand-coated microtitre plates. There are only
non-significant differences from lot to lot. For the
assays, purified fibronectin was used. Each value is the









































phase. All Systems showed aii optimal binding in
phosphate buffer containing bovine serum albumin
and EDTA and a broad pH optimum between pH
7.0 and 8.0. An exception was the IgGmod assay. Here,
we found a pH optimum at 6.0.
According to various investigations, raised ion con-
centrations will abolish heparin-fibronectin binding.
The addition of 0.15 mol/1 NaCl to the phosphate
buffer leads to an almost complete loss of fibronectin
binding to solid phase-tdünd heparin (data not
shown here).
To check the binding specificities, we performed as-
says in the presence of heparin, fibrinogen or gelatine
(fig. 2). These tests were carried out with purified
fibronectin. The fibrin assay was influenced by fibrin-
ogen, but not by gelatine or heparin. It has to be
mentioned here that the affinity of native fibrinogen
to fibronectin compared with that of fibrin is only
three percent (data not shown here). The gelatine
assay was inhibited by gelatine and remained unäf-
fected by heparin and fibrinogen. The heparin assay
was moderately stimulated by heparin, highly acti-
vated by gelatine and not affected by fibrinogen. The
binding assay for modified IgG was not altered by
any of the tested substances. Native IgG did not
influence any of the tests mentioned.
Figtire 3 illustrates the concentration-dependent in-
fluence of gelatine, fibrinogen and heparin on the
gelatine binding test. Soluble gelatine inhibited the
binding of fibronectin to solid «phase-bound gelatine
in a concentration-dependent'inanner. On the other
hand, heparin did not have any effect. This means
J. Clin. Chem. Clin. Biochem. / Vol. 24,1986 / No. 8
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Gelatine -assay
Fig. 3. Influence of dissolved fibrinogen, gelatine or heparii
Fig. 2. Interference of dissolved substances in the fibronectin
binding assays.
Column (1) represents in all binding assays the control
value. In the columns (2) 1.0 g/l fibrinogen, (3) 1.0 g/l
gelatine and (4) l U/ml heparin is added to the purifled
fibronectin. Fibronectin concentration (always set s
1.00) in the assays: fibrin assay: 10 mg/1, gelatine assay:
30 μg/l, heparin assay: 5 mg/1, IgG assay: 70 μg/l.
that dissolved heparin did not influence the gelatine
binding assay, but soluble gelatine massively pro-
moted fibronectin binding to coated heparin. For
further verification of this fmding, figure 4 demon-
strates the concentration-dependent influence of gela-
tine or heparin s well s the combined addition of
on the gelatine binding assay.
Purified fibronectin serves s Standard (30 μg/l = l .00).
The specified concentrations of the tested substances
(abscissa) relate to the initial sample material (concen-
tration in the test: l x l O"4).
both substances on the affinity of fibronectin for
solid phase-bound heparin. A low concentration of
dissolved heparin promoted the binding of fibronec-
tin to the solid phase-bound heparin. On the other
hand, higher concentrations inhibited binding of fi-
bronectin to the heparin-coated carrier. A quite dif-
ferent picture is shown in the 'gelatine-activation' of
heparin-fibronectin binding. Gelatine activated this
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Fig. 4. Influence of dissolved gelatine and heparin on the heparin binding assay.
a) Influence of dissolved heparin
b)
( ) control (A)
( ) 10 /ml heparin (B)
(._._) 50 U/ml heparin (C)
( ) 100 U/ml heparin (D)
( ) 500 U/ml heparin (E)
influence, of dissolved gelatine
(x x) control (A)
(· - ·) 10 mg/1 gelatine (B)
(o - o) 50 ing/1 gelatine (C)
(A-A) 100 mg/1 gelatine (D)
The specified concentrations of heparin and gelatine relate to the initial sample material (concentration in the test: l
10~2). Simultaneous addition of gelatine and heparin shows the binding kinetics of B.
J: Clin. Chem. Clin. Biociem. / Vol. 24,1986 / No. 8
546 Kotigen et al.: Functional analysis of plasma fibronectin
To check the immune reactivity and bioactivity of
fibronectin fragments, we incubated fibronectin with
thermolysin for various periods of time. The resulting
polypeptide chains were separated by polyacrylamide
gel electrophoresis and transferred to nitrocellulose
membranes (Western blot). Figure 5 shows that ther-
molysin treatment of fibronectin leads, in time-depen-
dent fashion, to an increasing cleavage of the protein.
Whereas some polypeptide fragments down to a mo-
lecular weight of Mr = ca. 30 000 were still immuno-
reactive, various larger fragments did not react with
anti-fibronectin. To support this finding, thermolysin-
treated fibronectin was separated on a hydroxyapatite
column. With this technique it is possible inter alia
to isolate the gelatine domain (Mr = 43000) (18).
The isolated peptide fragment was seen in the poly-
acrylamide gel electrophoresis after Coomassie stain-
ing at the expected molecular weight; however, it
could not be demonstrated immunologically in the
Western blot (fig. 5). The isolated peptide likewise
did not react in the gelatine assay (data not shown
here). However, we have indications that this isolated
fibronectin fragment can be quantified on the basis
of its carbohydrate moiety by an enzyme-linked lectin
assay (manuscript in preparation).
Data presented in figure 6 document the influence of
proteolysis on the binding assays and demonstrate at
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Fig. 5. Identification of fibronectin fragments after limited pro-
teolysis.
1: Polyacrylamide gel electrophoresis after Coomassie
staining. A = 15 s, B = 10 min, C = 3 h, D = 20 h
after beginning of the thermolysin proteolysis of fi-
bronectin; E = isolated gelatine binding domain of
fibronectin;
S = molecular weight Standards.
2: Material äs in 1. Representation of the immuno-
reactive polypeptides with anti-fibronectin in the West-
ern blot (see Methods). (<-) The gelatin binding domain
(MT = 43 000) shows no immunoreactivity.
have false positive or false negative effects on the test
Systems. In the antibody-based assay the thermolysin-
induced proteolysis of fibroiiectin leads to a massive
0 1 30 1801200 0 1





Heparin assayCarboxyl group-modif ied
Ig6 binding assay
Fig. 6. Proteolysis-dependent infiuence on the determination of fibronectin concentration.
The thermolysin-catalysed proteolysis of purified fibronectin *is stopped by addition of EDTA at defmed times (15s,
l min, 30 min, l h, 3 h, 5 h, 20 h). The samples are quantified in the individual assays, (o—o); antibody assay, gelatine
assay, fibrin assay, carboxyl group-modified IgG binding assay, heparin assay. , $
The fibronectin fragments are mixed with intact (purified) fibronectin (x-x). The horizontal bars correspond to the initial
concentration or binding activities of the intact molecuie (with consideration of the dilution factor).
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enhancement of the measured concentration. We ob-
tained almost identical false positive results with the
commercial turbidimetric fibronectin-assay. Prote-
olysis with trypsin or subtilisin interfered similarily.
Compared with the antibody assay, the functional
binding tests showed a quite difTerent picture. After
30 min of thermolysin treatment, all binding affinities
were no longer detectable.
To examine the question of whether fibronectin frag-
ments influence the functional quantification of intact
fibronectin, we mixed equal parts of native fibronec-
tin with fibronectin subjected to limited proteolysis.
Fibronectin fragments did not have any activating or
inhibiting effect on the gelatine, fibrin or IgG assay
(fig. 6). On the other band, in the heparin binding
test the low molecular weight fibronectin fragments
(after long thermolysin treatment) had a significant
inhibitory effect on the heparin binding activity of
native fibronectin.
In order to show to what extent the techniques pre-
sented here for human fibronectin can be transferred
to investigations with fibronectin of animal origin,
we tested plasma from rat, mouse, guinea pig, ham-
ster, calf, dog, sheep and rabbit. In the Western blot,
all samples, except rabbit plasma, showed immunore-
activity with anti-human fibronectin. We found no
cross-reactivity with other proteins. Table 2 demon-
strates that, with the exception of the fibrin binding
assay, the ligand-specific test Systems can be applied
to fibronectin studies in other animal species.
Tab. 2. Species-specificity of the fibronectin assays. In all as-
says EDTA plasma and anti-human fibronectin were
used. Predilutions of the plasma samples are described
in the text. The concentration and binding activities
are calculated from the Standard calibration curves (see
fig. 1). All values are the mean of triple determinations
































































In the present paper we describe highly sensitive
ELISA techniques for quantification of fibronectin,
together with studies on binding activities in biologi-
cal materials. At the same time, we show that in
many cases erroneous results are to be expected with
merely immunological assays of the fibronectin con-
centration. Hitherto, the most frequently applied
methods for the determination of fibronectin concen-
tration in plasma, cerebrospinal fluid, synovial fluid
or ascites have been immunological assays based on
turbidimetry, laser nephelometry or rocket immuno-
electrophoresis (21, 22, 23). Nevertheless, problems
in the quantification which greatly restrict the reliabil-
ity of these methods have been known for sortie time
(24). A further major disadvantage of the immuno-
logical quantification is that these techniques cannot
allow appraisals of the functional integrity of the
molecule. Both these facts probably explain the con-
tradictory opinions on the diagnostic and pathobio-
chemical relevance of fibronectin in various diseases
(25, 26). In view of these problems, other study
groups have already presented suggestions for the
functional analysis of fibronectin (15, 27, 28, 29). In
these gelatine and opsonin function-specified tests of
fibronectin, the possible interferences of fibronectin
domains have not been investigated. Other studies,
however, show that heparin leads to an exposure of
active domains via an alteration in conformation of
the fibronectin molecule (30, 31).
The individual techniques described here are charac-
terized by a high degree of sensitivity, good reproduc-
ibility and accuracy äs well äs good practicability.
The antibody assay is not interfered with by other
plasma proteins or other physiological plasma con-
stituents. However, it must be born in mind that
according to our results, äs already suspected by
other authors (24), proteolytic fibronectin fragments
also expose increased amounts of immunoreactive
determinants, so that fibronectin concentrations are
over-estimated. Other fibronectin fragments are no
longer immunoreactive (32). We confirm these find-
ings.
The question of the extent to which proteolytic frag-
ments have false positive or false negative effects on
the function tests could also be clarified. We show
that all binding affinities are destroyed by sufficiently
intensive exposure to proteases. At the same time,
we document in additional experiments with intact
fibronectin that late fibronectin fragments do not
disturb the binding capacity of native fibronectin. An
exception is the heparin assay. It shows a moderate
Inhibition at a high fragment concentration.
X Clin. Chem. Clin. Bipchem. / Vol. 24,1986 / No. 8
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To our knowledge, the described lest Systems present
the widest spectrum for a functional analysis of fi-
bronectin. At the same time, they provide the chance
of testing interference of the individual ligands. For
the quantification of the Collagen binding capacity
we used gelatine from calf skin äs ligand. Other
authors have shown that various collagen types pos-
sess a differentiated fibronectin binding behaviöur
(33). Since the collagen binding sites are localized
in the two N-terminal domains of the fibronectin
molecule and since fibrin and heparin are also bound
in this region, it had to be checked in particular
whether these two substances interfere with the gela-
tine binding assay. It becomes evident from our stud-
ies that soluble gelatine competitively inhibits the
binding of fibronectin to the solid phase-bound gela-
tine. However, neither heparin nor fibrinogen influ-
ence the test. A highly function-specific test is thus
provided. So far, it is not possible to assess how or
to what extent the two domains with collagen binding
affmity are involved in the gelatine test.
Fibronectin is bound covalently in the N-terminal
domain to the -chain of the fibrin monomer via the
transglutaminase activity of factor XIII. This binding
has no significance in our investigations with purified
fibronectin. In addition, the neighboring domain
binds fibrin, and it binds fibrinogen with reduced
affmity. Since collagen is also bound in this region,
our demonstration that the fibrin assay is preferen-
tially inhibited by fibrinogen, and to a lesser extent
also by gelatine, is understandable.
The binding affinity of fibronectin to carboxyl group-
modified IgG appears to be especially interesting,
since only the C-terminal domain is thought to be
responsible for this affinity (9). Otherwise only fibrin
(which does not interfere in any way with this test
System) is known to bind at this site. The specificity
of this binding also becomes evident, in that native
IgG does not have any influence. In clinical terms,
this test will be important, since there are indications
that the opsonin function of fibronectin involves this
binding type (34).
Glycosaminoglycans are bound by two domains of
the intact fibronectin molecule. An additional binding
domain is rendered reactive by limited proteolysis
(8). Whereas native fibronectin almost exclusively
binds heparin fragments of fibronectin can also bind
other proteoglycans with variable affinity. In the pre-
sent investigation, we were concerned only with hep-
arin. The N-terminal heparin-binding site is Ca2+-
inhibited, it can be assumed that mainly the N-ter-
minal binding site is detected in this heparin assay.
Fibrinogen does not interfere in the heparin assay.
Soluble heparin promotes fibronectin affinity to solid
phase-bound heparin at low conceiitration and in-
hibits this competitively at higher concentrations.
However, soluble gelatine induces a very impressive,
concentratioü-dependent enhancement of fibronectin
binding to the carrier-bound heparin. In cell adhesion
studies, an equivalent effect has already been ob-
served and designated äs "Substrate activation". Hep-
arin also significantly stimulates the fibronectin-medi-
ated uptake of gelatine-cöäted particles by macro-
phages (36). Thus, we have positive indications that
the results of our test system can be transferred to
studies in cell biology.
Further investigations are required to show to what
extent the effects observed here are also relevant for
in vivo functional regulation. This not only applies
to cell biological studies with use of additional ligands
and inhibitors, but also to the possible therapeutic
use of fibronectin in various 'active forms'. Positive
and negative reports on the use of fibronectin in
shock treatment and wound healing so far indicate
that further basic work is necessary (37, 38). Diag-
nostic use of the fibronectin function tests described
here also open new possibflities in the context of
inflammation and turnour diagnosis. Orientative in-
vestigations on plasma samples of patients with liver
diseases äs well äs of tumour patients suggest the
existence of marked differences and variations of the
fibronectin functional spectrum.
Finally, it is documented that the test System can also
be used for functional analysis of fibronectin of other
animal species, when using the appropriate animal
fibronectin Standards. Due to the high degree of
assay sensitivities, only minimal sample amounts are
needed. At the same time, these investigations already
show that fibronectins from different species have a
significantly different functional spectrum, showing
comparable concentrations in the antibody assay (ex-
cept dog) and significantly differing ratios between
the specific binding assays.
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